DAMORA THERAPEUTICS, INC. Increase (Decrease) in Prepaid Expense and Other Assets
DAMORA THERAPEUTICS, INC. (DMRA) reported Increase (Decrease) in Prepaid Expense and Other Assets of $274.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-10
- DAMORA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $564.00K.
- DAMORA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$290.00K, a 189.78% decline year-over-year.
- DAMORA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $620.00K, a 46.87% decline year-over-year.
- DAMORA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$637.00K.
- DAMORA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $138.00K.
- DAMORA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$954.00K.
- DAMORA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$65.00K.
- DAMORA THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$6.23M, a 248.42% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $564.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $274.00K 10-Q · filed 2026-08-10 | $894.00K derived: sum of 3 quarters · filed 2026-08-10 | $257.00K derived: sum of 4 quarters · filed 2026-08-10 | |
| 2026-03-31 | -$290.00K 10-Q · filed 2026-05-12 | $330.00K derived: sum of 2 quarters · filed 2026-05-12 | -$307.00K derived: sum of 3 quarters · filed 2026-05-12 | -$475.00K derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-12-31 | $620.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$17.00K derived: sum of 2 quarters · filed 2026-03-19 | -$185.00K derived: sum of 3 quarters · filed 2026-08-10 | $138.00K 10-K · filed 2026-03-19 | |
| 2025-09-30 | -$637.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$805.00K derived: sum of 2 quarters · filed 2026-08-10 | -$482.00K 10-Q · filed 2025-11-06 | $685.00K derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-06-30 | -$168.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $155.00K 10-Q · filed 2026-08-10 | $1.32M derived: sum of 3 quarters · filed 2026-08-10 | $518.00K derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-03-31 | $323.00K 10-Q · filed 2026-05-12 | $1.49M derived: sum of 2 quarters · filed 2026-05-12 | $686.00K derived: sum of 3 quarters · filed 2026-05-12 | -$379.00K derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $363.00K derived: sum of 2 quarters · filed 2026-03-19 | -$702.00K derived: sum of 3 quarters · filed 2026-03-19 | -$954.00K 10-K · filed 2026-03-19 | |
| 2024-09-30 | -$804.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.87M derived: sum of 2 quarters · filed 2025-11-06 | -$2.12M 10-Q · filed 2025-11-06 | -$1.37M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | -$1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$1.32M 10-Q · filed 2025-08-05 | -$570.00K derived: sum of 3 quarters · filed 2025-08-05 | -$932.00K derived: sum of 4 quarters · filed 2025-08-05 | |
| 2024-03-31 | -$252.00K 10-Q · filed 2025-05-08 | $495.00K derived: sum of 2 quarters · filed 2025-05-08 | $133.00K derived: sum of 3 quarters · filed 2025-05-08 | -$511.00K derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | $747.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $385.00K derived: sum of 2 quarters · filed 2025-03-19 | -$259.00K derived: sum of 3 quarters · filed 2025-03-19 | -$65.00K 10-K · filed 2025-03-19 | |
| 2023-09-30 | -$362.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-01 | -$1.01M derived: sum of 2 quarters · filed 2024-11-01 | -$812.00K 10-Q · filed 2024-11-01 | $758.00K derived: sum of 4 quarters · filed 2024-11-01 | |
| 2023-06-30 | -$644.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$450.00K 10-Q · filed 2024-08-12 | $1.12M derived: sum of 3 quarters · filed 2024-08-12 | $58.00K derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | $194.00K 10-Q · filed 2024-04-29 | $1.76M derived: sum of 2 quarters · filed 2024-04-29 | $702.00K derived: sum of 3 quarters · filed 2024-04-29 | $440.00K derived: sum of 4 quarters · filed 2024-04-29 | |
| 2022-12-31 | $1.57M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $508.00K derived: sum of 2 quarters · filed 2024-03-08 | $246.00K derived: sum of 3 quarters · filed 2024-03-08 | -$6.23M 10-K · filed 2024-03-08 | |
| 2022-09-30 | -$1.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$1.32M derived: sum of 2 quarters · filed 2023-11-06 | -$7.80M 10-Q · filed 2023-11-06 | -$3.61M derived: sum of 4 quarters · filed 2023-11-06 | |
| 2022-06-30 | -$262.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-31 | -$6.74M 10-Q · filed 2023-07-31 | -$2.55M derived: sum of 3 quarters · filed 2023-07-31 | -$2.72M derived: sum of 4 quarters · filed 2023-07-31 | |
| 2022-03-31 | -$6.48M 10-Q · filed 2023-04-28 | -$2.29M derived: sum of 2 quarters · filed 2023-04-28 | -$2.46M derived: sum of 3 quarters · filed 2023-04-28 | -$3.13M derived: sum of 4 quarters · filed 2023-04-28 | |
| 2021-12-31 | $4.19M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $4.02M derived: sum of 2 quarters · filed 2023-03-09 | $3.34M derived: sum of 3 quarters · filed 2023-03-09 | $4.20M 10-K · filed 2023-03-09 | |
| 2021-09-30 | -$175.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$848.00K derived: sum of 2 quarters · filed 2022-11-08 | $7.00K 10-Q · filed 2022-11-08 | -$849.00K 10-Q · filed 2021-11-04 | $383.00K derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | -$673.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-29 | $182.00K 10-Q · filed 2022-07-29 | $558.00K derived: sum of 3 quarters · filed 2022-07-29 | $2.33M derived: sum of 4 quarters · filed 2022-07-29 | |
| 2021-03-31 | $855.00K 10-Q · filed 2022-04-29 | $1.23M derived: sum of 2 quarters · filed 2022-04-29 | $3.01M derived: sum of 3 quarters · filed 2022-04-29 | $1.76M derived: sum of 4 quarters · filed 2022-04-29 | |
| 2020-12-31 | $376.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17 | $2.15M derived: sum of 2 quarters · filed 2022-02-17 | $905.00K derived: sum of 3 quarters · filed 2022-02-17 | $596.00K 10-K · filed 2022-02-17 | |
| 2020-09-30 | $1.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $529.00K derived: sum of 2 quarters · filed 2021-11-04 | $220.00K 10-Q · filed 2021-11-04 | $1.47M derived: sum of 4 quarters · filed 2021-11-04 | |
| 2020-06-30 | -$1.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$1.55M 10-Q · filed 2021-08-05 | -$302.00K derived: sum of 3 quarters · filed 2021-08-05 | ||
| 2020-03-31 | -$309.00K 10-Q · filed 2021-05-04 | $944.00K derived: sum of 2 quarters · filed 2021-05-04 | |||
| 2019-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $1.22M 10-K · filed 2021-03-29 | |||
| 2019-09-30 | -$33.00K 10-Q · filed 2020-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |